{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:24:20Z","timestamp":1791559460717,"version":"4.3.4"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Guselkumab has demonstrated favourable safety and efficacy across individual clinical studies in adults with moderate-to-severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the safety of guselkumab in patients with psoriasis using pooled data from seven phase II\/III studies (X-PLORE, VOYAGE 1, VOYAGE 2, NAVIGATE, ORION, ECLIPSE, Japan registration).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All studies, except NAVIGATE and ECLIPSE (active comparator-controlled only), included a 16-week placebo-controlled period; X-PLORE, VOYAGE 1 and VOYAGE 2 included both placebo and active controls. In most studies, guselkumab-treated patients received 100-mg subcutaneous injections at week 0, week 4, and then every 8 weeks thereafter. Safety data were summarized for the placebo-controlled period (weeks 0\u201316) and through the end of the reporting period (up to 5\u2005years). Incidence rates of key safety events were integrated post hoc, adjusted for the duration of follow-up and reported per 100 patient-years (PY).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the placebo-controlled period, 544 patients received placebo (165 PY) and 1220 received guselkumab (378 PY). Through the end of the reporting period, 2891 guselkumab-treated patients contributed 8662 PY of follow-up. During the placebo-controlled period, in the guselkumab and placebo groups, respectively, rates of adverse events (AEs) were 346\/100 PY and 341\/100 PY, and infections were 95.9\/100 PY and 83.6\/100 PY. Rates of serious AEs (6.3\/100 PY vs. 6.7\/100 PY), AEs leading to discontinuation (5.0\/100 PY vs. 9.7\/100 PY), serious infections (1.1\/100 PY vs. 1.2\/100 PY), malignancy (0.5 patients\/100 PY vs. 0.0 patients\/100 PY) and major adverse cardiovascular events (MACE; 0.3\/100 PY vs. 0.0\/100 PY) were low and comparable between guselkumab and placebo. Through the end of the reporting period, safety event rates were lower than or comparable to the placebo-controlled period in guselkumab-treated patients: AEs, 169\/100 PY; infections, 65.9\/100 PY; serious AEs, 5.3\/100 PY; AEs leading to discontinuation, 1.6\/100 PY; serious infections, 0.9\/100 PY; malignancy, 0.7\/100 PY; and MACE, 0.3\/100 PY. There were no cases of Crohn disease, ulcerative colitis, opportunistic infection or active tuberculosis related to guselkumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this comprehensive analysis of 2891 guselkumab-treated patients with psoriasis followed for up to 5\u2005years (8662 PY), guselkumab demonstrated favourable safety, consistent with previous reports. Safety event rates in guselkumab-treated patients were similar to those observed with placebo and were consistent throughout long-term treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljad115","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T11:49:54Z","timestamp":1680781794000},"page":"42-52","source":"Crossref","is-referenced-by-count":47,"title":["Safety of guselkumab treatment for up to 5\u2005years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure"],"prefix":"10.1093","volume":"189","author":[{"given":"Mark G","family":"Lebwohl","sequence":"first","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F","family":"Merola","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Department of Medicine, Division of Rheumatology and Immunology, Harvard Medical School, Brigham and Women\u2019s Hospital , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Rowland","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC , Horsham, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Miller","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC , Spring House, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Wen","family":"Yang","sequence":"additional","affiliation":[{"name":"Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson , Horsham, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Yu","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC , Spring House, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"You","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC , Spring House, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Chan","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC , Horsham, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8513-550X","authenticated-orcid":false,"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[{"name":"Institute and Comprehensive Center for Inflammatory Medicine, University of L\u00fcbeck , L\u00fcbeck , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G","family":"Langley","sequence":"additional","affiliation":[{"name":"Division of Clinical Dermatology & Cutaneous Science, Dalhousie University , Halifax, NS , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"2023100915270980000_ljad115-B1","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2023100915270980000_ljad115-B2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"2023100915270980000_ljad115-B3","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.jid.2021.02.764","article-title":"New frontiers in psoriatic disease research, part I: genetics, environmental triggers, immunology, pathophysiology, and precision medicine","volume":"141","author":"Yan","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2023100915270980000_ljad115-B4","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"4","author":"Sbidian","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2023100915270980000_ljad115-B5","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/03007995.2020.1776233","article-title":"The importance of understanding patient and physician preferences for psoriasis treatment characteristics: a systematic review of discrete-choice experiments","volume":"36","author":"Sain","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"2023100915270980000_ljad115-B6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","article-title":"Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents","volume":"80","author":"Kaushik","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2023100915270980000_ljad115-B7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","article-title":"Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections","volume":"80","author":"Kaushik","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2023100915270980000_ljad115-B8","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/bjd.20568","article-title":"Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2","volume":"185","author":"Reich","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023100915270980000_ljad115-B9","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/14740338.2018.1488963","article-title":"A safety evaluation of guselkumab for the treatment of psoriasis","volume":"17","author":"Galluzzo","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"2023100915270980000_ljad115-B10","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaad.2021.11.004","article-title":"Consistent safety profile with up to 5\u2005years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2023100915270980000_ljad115-B11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1501646","article-title":"A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis","volume":"373","author":"Gordon","year":"2015","journal-title":"N Engl J Med"},{"key":"2023100915270980000_ljad115-B12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2023100915270980000_ljad115-B13","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2023100915270980000_ljad115-B14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"key":"2023100915270980000_ljad115-B15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09546634.2019.1587145","article-title":"Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study","volume":"31","author":"Ferris","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"2023100915270980000_ljad115-B16","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"2023100915270980000_ljad115-B17","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/1346-8138.14504","article-title":"Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study","volume":"45","author":"Ohtsuki","year":"2018","journal-title":"J Dermatol"},{"key":"2023100915270980000_ljad115-B18","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"14","author":"Papp","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"2023100915270980000_ljad115-B19","first-page":"571","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) erratum","volume":"19","author":"Papp","year":"2020","journal-title":"J Drugs Dermatol"},{"issue":"3 Suppl.","key":"2023100915270980000_ljad115-B20","first-page":"AB1\u2013338","article-title":"Safety of guselkumab in patients with moderate to severe psoriasis: pooled analyses across clinical studies","volume":"87","author":"Lebwohl","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2023100915270980000_ljad115-B21","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/bjd.14068","article-title":"Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States","volume":"173","author":"Kimball","year":"2015","journal-title":"Br J Dermatol"},{"key":"2023100915270980000_ljad115-B22","author":"National Cancer Institute"},{"key":"2023100915270980000_ljad115-B23","doi-asserted-by":"crossref","DOI":"10.1093\/bjd\/ljad081","article-title":"Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials","volume":"189","author":"Blauvelt","year":"2023","journal-title":"Br J Dermatol"},{"key":"2023100915270980000_ljad115-B24","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s13555-022-00687-0","article-title":"A practical guide to the management of oral candidiasis in patients with plaque psoriasis receiving treatments that target interleukin-17","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2023100915270980000_ljad115-B25","first-page":"545","article-title":"Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management","volume":"156","author":"Rodr\u00edguez-Cerdeira","year":"2021","journal-title":"Ital J Dermatol Venerol"},{"key":"2023100915270980000_ljad115-B26","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamadermatol.2022.1185","article-title":"Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from phase 2 and phase 3 randomized clinical trials","volume":"158","author":"Gordon","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2023100915270980000_ljad115-B27","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.563","article-title":"Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data","volume":"102","author":"Gottlieb","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"2023100915270980000_ljad115-B28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s13555-019-00340-3","article-title":"Safety of ixekizumab treatment for up to 5\u2005years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure","volume":"10","author":"Armstrong","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2023100915270980000_ljad115-B29","doi-asserted-by":"crossref","first-page":"855","DOI":"10.36849\/JDD.6216","article-title":"Serious gastrointestinal-related adverse events among psoriasis patients treated with guselkumab in VOYAGE 1 and VOYAGE 2","volume":"20","author":"Foley","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"2023100915270980000_ljad115-B30","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjd.20818","article-title":"Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis","volume":"186","author":"Gordon","year":"2022","journal-title":"Br J Dermatol"},{"key":"2023100915270980000_ljad115-B31","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjd.18232","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"2023100915270980000_ljad115-B32","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/annrheumdis-2012-202143","article-title":"Psoriasis, psoriatic arthritis and increased risk of incident Crohn\u2019s disease in US women","volume":"72","author":"Li","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2023100915270980000_ljad115-B33","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023100915270980000_ljad115-B34","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"; Secukinumab in Crohn\u2019s Disease Study Group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"2023100915270980000_ljad115-B35","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn\u2019s disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2023100915270980000_ljad115-B36","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D'Haens","year":"2022","journal-title":"Lancet"},{"key":"2023100915270980000_ljad115-B37","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"2023100915270980000_ljad115-B38","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"; GALAXI-1 Investigators. Guselkumab for the treatment of Crohn\u2019s disease: induction results from the phase 2 GALAXI-1 study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"issue":"Suppl. 1","key":"2023100915270980000_ljad115-B39","doi-asserted-by":"crossref","first-page":"i025","DOI":"10.1093\/ecco-jcc\/jjab232.022","article-title":"The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active ulcerative colitis: phase 2b QUASAR study results through week 12","volume":"16","author":"Dignass","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2023100915270980000_ljad115-B40","author":"Bausch Health"},{"key":"2023100915270980000_ljad115-B41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaad.2017.08.024","article-title":"Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials","volume":"78","author":"Lebwohl","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2023100915270980000_ljad115-B42","first-page":"119","article-title":"Examining worldwide postmarketing suicides from biologics used for psoriasis with a focus on brodalumab: a cross-sectional analysis using the FDA Adverse Event Reporting System (FAERS)","volume-title":"JAAD Int","author":"Yeroushalmi","year":"2022"},{"key":"2023100915270980000_ljad115-B43","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012567","article-title":"Risk of tuberculosis in patients treated with TNF-\u03b1 antagonists: a systematic review and meta-analysis of randomised controlled trials","volume":"7","author":"Zhang","year":"2017","journal-title":"BMJ Open"},{"key":"2023100915270980000_ljad115-B44","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1111\/jdv.16460","article-title":"Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials","volume":"34","author":"Puig","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100915270980000_ljad115-B45","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug-induced hepatotoxicity: concise up-to-date review","volume":"23","author":"Tostmann","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"2023100915270980000_ljad115-B46","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","article-title":"Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review","volume":"22","author":"Thatiparthi","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2023100915270980000_ljad115-B47","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/jdv.15653","article-title":"Safety of selective IL-23p19 inhibitors for the treatment of psoriasis","volume":"33","author":"Crowley","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100915270980000_ljad115-B48","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjd.13013","article-title":"; PSOLAR Steering Committee. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad115\/50394109\/ljad115.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/1\/42\/51959322\/ljad115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/1\/42\/51959322\/ljad115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T11:30:04Z","timestamp":1696851004000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/189\/1\/42\/7109972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,4,6]]},"published-print":{"date-parts":[[2023,7,7]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad115","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7]]},"published":{"date-parts":[[2023,4,6]]}}}